Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance

Journal of Clinical Psychopharmacology

Volumn 22, Issue 6, 2002, Pages 576-583

  Verster, Joris C ^a   Volkerts, Edmund R ^a   Schreuder, Antonia H C M L ^a   Eijken, Erik J E ^a   Van Heuckelum, Janet H G ^a   Veldhuijzen, Dieuwke S ^a   Verbaten, Marinus N ^a   Paty, Isabelle ^b   Darwish, Mona ^c   Danjou, Philippe ^b   Patat, Alain ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Searle European Clinical R and D   (France)

^c WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; HYPNOTIC SEDATIVE AGENT; PLACEBO; ZALEPLON; ZOLPIDEM;

ADULT; AMNESIA; ARTICLE; ASTHENIA; ATAXIA; ATTENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIPLOPIA; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; DRUG EFFECT; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY; MOTOR DYSFUNCTION; NAUSEA; NIGHT; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RECALL; SINGLE BLIND PROCEDURE; SOMNOLENCE; TASK PERFORMANCE; THOUGHT DISORDER; VELOCITY; VERTIGO; VOMITING; XEROSTOMIA;

ACETAMIDES; ADULT; AUTOMOBILE DRIVING; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHANOL; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MEMORY; PSYCHOMOTOR PERFORMANCE; PYRIDINES; PYRIMIDINES; SINGLE-BLIND METHOD; TASK PERFORMANCE AND ANALYSIS; TIME FACTORS;

EID: 0036896870     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200212000-00007     Document Type: Article

References (30)

1. Van Laar MW, Volkerts ER. Driving and benzodiazepine use: Evidence that they do not mix. CNS Drugs 1998;10:383-96.
2. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998;64:553-61.
3. Dämgen K, Lüddens H. Zaleplon displays a selectivity to recombinant GABAA receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 1999;25:139-48.
4. Dooley M, Plosker GL. Zaleplon: A review of its use in the treatment of insomnia. Drugs 2000;60:413-45.
5. Holm KJ, Goa KL. Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000;59:865-89.
6. Berlin I, Warot D, Hergueta T, et al. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 1993;13:100-6.
7. Richens A, Mercer AJ, Jones DM, et al. Effects of zolpidem on saccadic eye movements and psychomotor performance: A doubleblind, placebo-controlled study in healthy volunteers. Br J Clin Pharmacol 1993;36:61-5.
8. Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory, and performance effects of hypnotics. Psychopharmacology 1994;116:130-4.
9. Wesensten NJ, Balkin TJ, Belenky GL. Effects of daytime administration of zolpidem versus triazolam on memory. Eur J Clin Pharmacol 1995;48:115-22.
10. Wesensten NJ, Balkin TJ, Belenky GL. Effects of daytime administration of zolpidem and triazolam on performance. Aviat Space Environ Med 1996;67:115-20.
11. Mattila MJ, Vanakoski J, Kalska H, et al. Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol Biochem Behav 1998;59:917-23.
12. Rush CR, Armstrong DL, Ali JA, et al. Benzodiazepine-receptor ligands in humans: Acute performance-impairing, subject-rated and observer-rated effects. J Clin Psychopharmacol 1998;18:154-66.
13. Danjou P, Paty I, Fruncillo R, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol 1999;48:367-74.
14. Mintzer MZ, Griffiths RR. Selective effects of zolpidem on human memory functions. J Psychopharmacol 1999;13:18-31.
15. Mintzer MZ, Griffiths RR. Triazolam and zolpidem: Effects on human memory and attentional processes. Psychopharmacology 1999;144:8-19.
16. Drover D, Lemmeus H, Naidu S, et al. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 2000;22:1443-61.
17. Troy SM, Lucki I, Unruh MA, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 2000;20:328-37.
18. Hindmarch I, Patat A, Stanley N, et al. Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. Hum Psychopharmacol Clin Exp 2001;16:159-67.
19. Vermeeren A, O'Hanlon JF, Declerck AC, et al. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Therapeutica 1995;21:47-64.
20. Bocca ML, Le Doze F, Etard O, et al. Residual effects of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology 1999;143:373-9.
21. Bensimon G, Foret J, Warot D, et al. Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo. Br J Clin Pharmacol 1990;30:463-9.
22. Quera-Salva MA, McCann C, Boudet J, et al. Effects of zolpidem on sleep architecture, night time ventilation, daytime vigilance and performance in heavy snorers. Br J Clin Pharmacol 1994;37:539-43.
23. Vermeeren A, Danjou PE, O'Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol Clin Exp 1998;13:S98-107.
24. Vermeeren A, Muntjeweiff ND, Van Boxtel MPJ, et al. Residual effects of zaleplon and zopiclone versus the effects of alcohol on actual car driving performance. Eur Neuropsychopharmacol 2000; 10[suppl 3]:S394.
25. Volkerts ER, van Laar MW, van Willigenburg APP, et al. A comparative study of on-the-road and simulated driving performance after nocturnal treatment with lormetazepam 1 mg and oxazepam 50 mg. Hum Psychopharmacol 1992;7:297-309.
26. O'Hanlon JF, Vermeeren A, Uiterwijk MM, et al. Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test: An integration of three studies. Neuropsychobiology 1995;31:81-8.
27. Van Laar MW, van Willigenburg AP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 1995;15:30-40.
28. Riedel WJ, Vermeeren A, van Boxtel MPJ, et al. Mechanisms of drug-induced impairments: A dimensional approach. Hum Psychopharmacol 1998;13:S49-63.
29. Logan BK, Couper FJ. Zolpidem and driving impairment. J Forensic Sci 2001;46:105-10.
30. Volkerts ER, Van Laar M. Specific review of the psychometric effects of cetirizine. Allergy 1995;50:55-60.